FindTrial
Sign In

Comparison of the effectiveness of a synergistic formulation of a combination cream (clindamycin, camel milk exosome, and aloe vera) with clindamycin for the treatment of acneiform rash caused by the chemotherapy drug cetuximab: A technological and applied study in the field of dermatological drugs

Comparison of the effectiveness of a synergistic formulation of a combination cream (clindamycin, camel milk exosome, and aloe vera) with clindamycin for the treatment of acneiform rash caused by the chemotherapy drug cetuximab: A technological and applied study in the field of dermatological drugs

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250427065485N1
Enrollment
12
Registered
2025-05-08
Start date
2025-05-22
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with skin rash caused by cetuximab.

Interventions

Intervention group: 12 patients with cetuximab-induced skin rash.

Sponsors

Birjand University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient with cetuximab-induced skin rash with similar clinical conditions

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The rate of skin rashes caused by cetuximab. Timepoint: Before the start of the intervention and 4 weeks later. Method of measurement: Score-Skin to assess the reduction of erythema, papules, pustules and itching and DLQI questionnaire to assess the impact of skin manifestations on patients' quality of life.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Karbasi

Birjand University of Medical Sciences

s.karbasi@bums.ac.ir+98 56 3239 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026